BBI Life Sciences Stages $37 Million IPO in Hong Kong

Published: Feb 05, 2015

February 5, 2015 -- BBI Life Sciences, a Shanghai-based lab services company, has completed a US$37.4 million IPO in Hong Kong. BBI provides DNA synthesis products, genetic engineering services, life sciences research consumables and protein/antibody services to researchers in China, the US and Europe. BBI claims a 17.4% share of China's DNA synthesis market, making it the largest company in that field. Qiming Ventures was an early investor in BBI.

Help employers find you! Check out all the jobs and post your resume.

Back to news